Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Vyndaqel“
Suchtreffer
Begriffe & Kennungen
Vyndaqel
Eintrag öffnenVyndaqel · 4.1 Therapeutic indications · 1
Eintrag öffnenVyndaqel · 4.1 Therapeutic indications · 2
Eintrag öffnenVyndaqel · 4.1 Therapeutic indications · 3
Eintrag öffnenVyndaqel · 4.3 Contraindications · 1
Eintrag öffnenVyndaqel · 4.3 Contraindications · 2
Eintrag öffnenVyndaqel · 4.3 Contraindications · 3
Eintrag öffnenVyndaqel · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenVyndaqel · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenVyndaqel · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenVyndaqel · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenVyndaqel · 4.4 Special warnings and precautions for use · 2
Eintrag öffnenVyndaqel · 4.4 Special warnings and precautions for use · 3
Eintrag öffnenVyndaqel · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenVyndaqel · 4.5 Interaction with other medicinal products and other forms of interaction · 2
Eintrag öffnenVyndaqel · 4.5 Interaction with other medicinal products and other forms of interaction · 3
Eintrag öffnenVyndaqel · 4.5 · 3 daily doses of 61 mg tafamidis. Therefore, patients should be monitored for BCRP substrate related adverse r
Eintrag öffnenVyndaqel · 4.5 · In a clinical study in healthy volunteers, 20 mg tafamidis meglumine did not induce or inhibit the cytochrome
Eintrag öffnenVyndaqel · 4.5 · In a clinical study in healthy volunteers, 20 mg tafamidis meglumine did not induce or inhibit the cytochrome
Eintrag öffnenVyndaqel · 4.5 · In a clinical study in healthy volunteers, 20 mg tafamidis meglumine did not induce or inhibit the cytochrome
Eintrag öffnen